Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia

Clé, Diego V.; Santana-Lemos, Bárbara A.; Tellechea, Maria Florencia; Prata, Karen Lima; Orellana, Maristela Delgado; Covas, Dimas Tadeu; Calado, Rodrigo T.

doi:10.1016/j.jcyt.2015.09.006

Cited by 25 publications

(26 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In six patients, two achieved a complete response including recovery of three hematopoietic cell lines after MSCs therapy. Similar results was achieved by Cle et al 2015 using MSCs being 22% of all patients (18 patients) presents hematologic response at 6 months after MSCs transplantation [108]. One clinical trial phase II conducted in China evaluated the MSC overall response rate and safety using a significant number of refractory AA younger patients (n = 72).…”

Section: Clinical Studies With Msc For Treat Aasupporting

confidence: 65%

“…One patient with RAEB-II died of disease progression, two patients died of intracranial hemorrhages, and six patients died of serious infection [107]. In other two studies were reported adverse events such as, fever, hypoxemia, mild dyspnea and diarrhea during MSCs administration or some hours after MSCs injection, this phenomenon occurs in 2 of 16 patients [107] and 7 of the 18 patients [108]. None major adverse effects were reported in all studies during months of follow-up of each respective study.…”

Section: Clinical Studies With Msc For Treat Aamentioning

confidence: 96%

See 1 more Smart Citation

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Gonzaga¹,

Policiquio²,

Wenceslau³

et al. 2021

Human Blood Group Systems and Haemoglobinopathies

View full text Add to dashboard Cite

Acquired aplastic anemia (AA) is characterized by partial or total bone marrow (BM) destruction resulting in pancytopenia. Most of the acquired AA is the result of autoimmune condition the imbalance between T-regulatory cells (Treg), abnormal cytokines production and cytotoxic T cells activation, leading to the hematopoietic stem cells (HSCs) death. The first-line treatment is given by HSC transplant, but some patients did not respond to the treatment. Therefore, new technologies need to treat AA nonresponder patients. Studies are in progress to test the efficacy of stem cell-based therapeutic as mesenchymal stem cells (MSCs), which confer low immunogenicity and are reliable allogeneic transplants in refractory severe AA cases. Furthermore, MSCs comprise the BM stromal niche and have an important role in supporting hematopoiesis by secreting regulatory cytokines, providing stimulus to natural BM microenvironment. In addition, MSCs have immunomodulatory property and are candidates for efficient supporting AA therapy.

show abstract

Section: Clinical Studies With Msc For Treat Aasupporting

confidence: 65%

Section: Clinical Studies With Msc For Treat Aamentioning

confidence: 96%

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Gonzaga¹,

Policiquio²,

Wenceslau³

et al. 2021

Human Blood Group Systems and Haemoglobinopathies

View full text Add to dashboard Cite

show abstract

“…All patients received one intravenous (dorsal hand vein) infusion of ABMSCs, of which the total number for each patient was 3 × 10 6 /kg [22][23][24][25], sequentially infused within 30 min. Before transplantation, close monitoring of vital signs was performed including measurements of body temperature, blood glucose, blood pressure, pulse, blood oxygen saturation, and an electrocardiogram.…”

Section: Treatmentmentioning

confidence: 99%

Efficacy and Safety of Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with Diabetic Retinopathy

Zhao

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The treatment options for diabetic retinopathy (DR) are limited. Mesenchymal stem cells (MSCs) are a promising treatment option for diabetes and its complications. In this pilot clinical trial, we evaluated the safety and efficacy of intravenous autologous bone marrow MSCs (ABMSC) for the treatment of DR. Methods: In total, 34 eyes with non-proliferative or proliferative DR (NPDR, n = 19; PDR, n = 15) from 17 patients were analyzed. Treatment involved one intravenous infusion of 3 × 10⁶/kg ABSMCs. The patients’ vital signs were monitored, along with immune and allergic reactions. Treatment efficacy was evaluated via measurements of the following parameters at baseline, and at 1, 3, and 6 months after treatment: the levels of fasting blood glucose (FBG), Hemoglobin A1C (HbA_1C), interleukin-6 (IL-6), and hypersensitive C-reactive protein (CRP); best corrected visual acuity (BCVA); and central macular and subfield thickness (via optical computed tomography). Results: ABMSC infusion led to a significant decrease in FBG and CRP levels (P < 0.05). There were no significant differences in HbA_1C or IL-6 levels. Sub-group analysis revealed that only eyes in the NPDR group had the macular thickness reductions and a significant improvement in BCVA from baseline (P = 0.006 at 3 months and 0.027 at 6 months), while those in the PDR group did not. There were no acute reactions during the treatment or severe adverse events during the follow-up period. Conclusion: ABSMCs are a potentially safe and effective treatment option for DR, and the optimum therapeutic window appears to be during the NPDR stage.

show abstract

“…However, previous studies also reported the clinical application of BM-MSCs is not matched with donor, host immune rejection or graft versus host reaction (50)(51)(52). Moreover, allogeneic bone marrow transplantation of mesenchymal stem cells in severe idiopathic aplastic anemia patients have also been shown to improve the effect of bone marrow stromal function (53,54). Allogeneic transplantation of BM-MSCs not only has ability of multi-directional differentiation, but also has special immune tolerance, allowing them to survive in allogeneic environment, in which provides a possibility for the application of BM-MSCs MI therapy.…”

Section: Remaining Problems and Future Directionsmentioning

confidence: 99%

Into the eyes of bone marrow-derived mesenchymal stem cells therapy for myocardial infarction and other diseases

Li¹,

Qu²

2017

Stem Cell Investig.

View full text Add to dashboard Cite

Applications of bone marrow-derived mesenchymal stem cells (BM-MSCs) have been documented for diseases occur in the sports system, the central nervous system, the cardiovascular system etc. However, poor viability of donor stem cells after transplantation limits their therapeutic efficiency. Although the autophagy theory has been reported, the underlying mechanisms are still poorly understood. Isolation and culture methods of mesenchymal stem cells are currently concentrate on four ways. Overall, BM-MSCs have both important research significance and clinical application value in cell replacement therapy, gene therapy and reconstruction of tissues as well as organs especially for myocardial infarction (MI). In this article, we review the biological characteristics of BM-MSCs and its research progress especially in MI. bone marrow which has aroused people's interest (1,4,5). Furthermore, BM-MSCs can act as support hematopoietic cells, promoting the growth of hematopoietic stem cells. Above all, BM-MSCs have broad application prospects in tissue engineering, cell transplantation and gene therapy because of the advantages of easy separation, amplification and easy operation in vitro and in vivo (6)(7)(8)(9). Taken together, BM-MSCs have important research significance and clinical application value in cell replacement therapy, gene therapy and tissue regeneration. In this article we review the latest progress, limitation as well as clinical application of BMMSCs. Isolation of BM-MSCsBM-MSCs are obtained mainly from bone marrow aspiration, while human BM-MSCs are generally drawn from the anterior superior iliac spine (10). They are also available from the tibia, femur, sternum, lumbar spine. The acquisition sites of BM-MSCs in large animals are the same as humans, however, rabbits' BM-MSCs need to be extracted in the middle of the tibia or femur bone marrow (11-13). The proportion of BM-MSCs nucleated cell population accounts for less than 0.0001% of them, however they can easily be isolated and expanded by using certain cell culture techniques (10). Stro-1 monoclonal antibody is usually used to isolate BM-MSCs which grow by attaching to the wall in laminin adhesion culture plate with low concentration of serum and CD45-/A-glycoproteins (14). In the past, BM-MSCs isolation methods were mainly concentrated on density gradient centrifugation method, differential adherence screening method, flow cytometry sorting method as well as immune beads method (15). However, high purity of BM-MSCs cannot be obtained by the four kinds of separation methods as described above. Nowadays, selecting the appropriate factor based on different reactivity of BM-MSCs to growth factors, to stimulate the proliferation, obtaining a higher proportion the mesenchymal stem cells has been regarded as a more accurate isolation method. Meanwhile, the new method of using 3 microns diameter plastic petri dish to screen BMMSCs, whose homogeneity are greater than 98%, with capacity of proliferation, self-renewal and have the potential to diff...

show abstract

Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia

Cited by 25 publications

References 46 publications

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment

Efficacy and Safety of Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with Diabetic Retinopathy

Into the eyes of bone marrow-derived mesenchymal stem cells therapy for myocardial infarction and other diseases

Contact Info

Product

Resources

About